about
The endocrine influence on the bone microenvironment in early breast cancerEfficacy of eribulin in breast cancer: a short report on the emerging new data.Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover.Reproductive hormones in breast cancer bone metastasis: The role of inhibins.Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study.Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?CDK4/6 inhibitors in breast cancer - from in vitro models to clinical trials
P50
Q28080154-9EB8F77B-3381-4AD6-A686-405A477EE29FQ31167441-44DEB225-7AA2-4568-A2BB-2EB1475CE8EFQ36661462-EDE345A0-5468-47AA-B895-F03C1EC89068Q37337495-758B156F-4831-47E9-9488-7F191220410EQ37645161-966BEAFA-D1EE-426F-81A1-4B33D050BF9CQ38230839-542ED836-E88E-41EB-8E9A-1C570A2F3779Q47110989-78D5D14B-951B-48F8-9EC7-FF6739BBD741Q90289461-40911F86-C514-40B3-ACA7-5BA587AED407Q91034441-1410CBB2-29F6-49B9-84E0-5F40076818B8
P50
description
researcher (ORCID 0000-0003-1769-7169)
@en
name
Caroline Wilson
@en
type
label
Caroline Wilson
@en
prefLabel
Caroline Wilson
@en
P31
P496
0000-0003-1769-7169